- Home
- QLGN vs ADTX Comparison
QLGN vs ADTX Comparison
Compare QLGN & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- ADTX
- Stock Information
- Founded
- QLGN 1996
- ADTX 2017
- Country
- QLGN United States
- ADTX United States
- Employees
- QLGN N/A
- ADTX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- ADTX Health Care
- Exchange
- QLGN Nasdaq
- ADTX Nasdaq
- Market Cap
- QLGN 3.1M
- ADTX 3.1M
- IPO Year
- QLGN N/A
- ADTX 2020
- Fundamental
- Price
- QLGN $1.90
- ADTX $1.02
- Analyst Decision
- QLGN
- ADTX
- Analyst Count
- QLGN 0
- ADTX 0
- Target Price
- QLGN N/A
- ADTX N/A
- AVG Volume (30 Days)
- QLGN 125.5K
- ADTX 434.2K
- Earning Date
- QLGN 08-26-2025
- ADTX 08-14-2025
- Dividend Yield
- QLGN N/A
- ADTX N/A
- EPS Growth
- QLGN N/A
- ADTX N/A
- EPS
- QLGN N/A
- ADTX N/A
- Revenue
- QLGN N/A
- ADTX $12,051.00
- Revenue This Year
- QLGN N/A
- ADTX $15,768.94
- Revenue Next Year
- QLGN N/A
- ADTX N/A
- P/E Ratio
- QLGN N/A
- ADTX N/A
- Revenue Growth
- QLGN N/A
- ADTX N/A
- 52 Week Low
- QLGN $1.61
- ADTX $0.81
- 52 Week High
- QLGN $11.50
- ADTX $11,700.00
- Technical
- Relative Strength Index (RSI)
- QLGN 32.76
- ADTX 40.91
- Support Level
- QLGN $1.61
- ADTX $0.99
- Resistance Level
- QLGN $1.91
- ADTX $1.29
- Average True Range (ATR)
- QLGN 0.16
- ADTX 0.11
- MACD
- QLGN -0.01
- ADTX 0.01
- Stochastic Oscillator
- QLGN 26.48
- ADTX 44.21
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.